Clinical Trial Update: A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating whether reducing daily ICS/LABA maintenance to an anti-inflammatory reliever approach is feasible in severe eosinophilic asthma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Eosinophilic Asthma

Drugs mentioned

• FASENRA (BENRALIZUMAB)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma, Severe Eosinophilic Asthma | Phase 4 | Status: COMPLETED | Results posted: 2025-01-09